Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patients

Currently, amrubicin is permitted for relapsed small-cell lung carcinoma (SCLC) only in Japan. The efficacy and adverse effects of amrubicin as reported by previous studies varied greatly. The inclusion criterion was a prospective study that was able to provide data for efficacy and safety by the AM...

Descripción completa

Detalles Bibliográficos
Autores principales: Horita, Nobuyuki, Yamamoto, Masaki, Sato, Takashi, Tsukahara, Toshinori, Nagakura, Hideyuki, Tashiro, Ken, Shibata, Yuji, Watanabe, Hiroki, Nagai, Kenjiro, Nakashima, Kentaro, Ushio, Ryota, Ikeda, Misako, Kobayashi, Nobuaki, Shinkai, Masaharu, Kudo, Makoto, Kaneko, Takeshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707435/
https://www.ncbi.nlm.nih.gov/pubmed/26750506
http://dx.doi.org/10.1038/srep18999

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4707435/
https://www.ncbi.nlm.nih.gov/pubmed/26750506
http://dx.doi.org/10.1038/srep18999

Ejemplares similares